Regulatory Approval (ANDA)
Glenmark Receives USFDA Approval for Progesterone Vaginal Inserts (100 mg)
NSE
glenmark
BSE
532296
Glenmark has received final USFDA approval for Progesterone Vaginal Inserts (100 mg), targeting the U.S. market with a product equivalent to Endometrin®, with a market size of ~$59.2 million.
PRICE-SENSITIVE TRIGGER
Event: USFDA approval
Type: Regulatory Approval (ANDA)
Impact: Positive
Immediate Effect: U.S. product portfolio and revenue opportunity
Key Metrics
- Product: Progesterone Vaginal Inserts, 100 mg
Highlights
US Market Opportunity: $59.2 million
What Happened ?
Glenmark Pharmaceuticals Limited announced that it has received final approval from the US Food & Drug Administration (USFDA) for Progesterone Vaginal Inserts, 100 mg
The product is bioequivalent and therapeutically equivalent to the reference drug Endometrin®.
Key details
Product Overview
- Drug: Progesterone Vaginal Inserts (100 mg)
- Reference Drug: Endometrin®
- Indication: Women’s healthcare
Market Opportunity
- U.S. annual sales: ~$59.2 million
- Based on IQVIA data
Commercialisation
- To be marketed in the U.S.
- Distributed via Glenmark Pharmaceuticals Inc., USA
Strategic Importance
- Strengthens U.S. generics portfolio
- Expands presence in women’s healthcare segment
- Enhances pipeline of approved products
Risk Analysis
Key Risks
- Pricing pressure in U.S. generics
- Competition from existing players
- Limited market size
Worst Case Scenario
Low margins reduce profitability impact
Risk Level: Low
Company Commentary
- Focus on expanding access to affordable medicines
- Strengthening U.S. portfolio
- Continued growth in specialty segments
Official Exchange Filing: Glenmark Pharmaceuticals Limited